Local therapy for metastatic NSCLC: in conversation with Fiona McDonald
We recently had the opportunity to speak with Consultant Clinical Oncologist Fiona McDonald (The Royal Marsden NHS Foundation Trust, London, UK) about the evolving role of stereotactic radiotherapy in treating different patterns of oligometastatic lung cancer.
In this video, discover insights on key NSCLC clinical trials, including the SINDAS, CURB and the NorthStar study. Fiona also discusses the challenge of keeping pace with rapidly advancing drug therapies and the need for better patient selection to identify which patients will benefit most.
SAVE THE DATE – 17th November 2027 – The 10th Royal Marsden Lung Cancer Symposium.
Interviewee profile:
Dr Fiona McDonald is a Consultant Thoracic Clinical Oncologist at The Royal Marsden NHS Foundation Trust and is a member of faculty at the Institute of Cancer Research (London, UK). Her research aims to improve outcomes by developing individualized approaches to radiotherapy through integration of targeted biological agents and immunotherapy with advanced radiotherapy technologies, including stereotactic radiotherapy, intensity-modulated and image-guided adaptive radiotherapy.
She is the chief investigator for the HALT trial investigating SBRT in oligo-progressive disease in patients with mutation-positive NSCLC and the SARON trial investigating SBRT in synchronous oligo-metastatic NSCLC.
Fiona’s additional national roles include chair of the UK SABR consortium and steering committee member of the British Thoracic Oncology Group. Internationally, she’s chaired the ESTRO Guidelines Committee and chair of the Advanced Radiotherapy Committee of the International Association for the Study of Lung Cancer (IASLC).
The opinions expressed in this interview are those of the author and do not necessarily reflect the views of Oncology Central or Taylor & Francis Group.